154 related articles for article (PubMed ID: 26093061)
1. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
Burger IA; Goldman DA; Vargas HA; Kattan MW; Yu C; Kou L; Andikyan V; Chi DS; Hricak H; Sala E
Gynecol Oncol; 2015 Sep; 138(3):554-9. PubMed ID: 26093061
[TBL] [Abstract][Full Text] [Related]
2. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
[TBL] [Abstract][Full Text] [Related]
3. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
Janco JM; Kumar A; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Apr; 141(1):140-7. PubMed ID: 26836496
[TBL] [Abstract][Full Text] [Related]
4. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
[TBL] [Abstract][Full Text] [Related]
5. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
[TBL] [Abstract][Full Text] [Related]
6. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
[TBL] [Abstract][Full Text] [Related]
7. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery.
Rutten IJ; Ubachs J; Kruitwagen RF; van Dijk DP; Beets-Tan RG; Massuger LF; Olde Damink SW; Van Gorp T
Eur J Surg Oncol; 2017 Apr; 43(4):717-724. PubMed ID: 28159443
[TBL] [Abstract][Full Text] [Related]
8. Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?
Lorusso D; Sarno I; Di Donato V; Palazzo A; Torrisi E; Pala L; Marchiano A; Raspagliesi F
Oncology; 2014; 87(5):293-9. PubMed ID: 25139548
[TBL] [Abstract][Full Text] [Related]
9. Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
Kumar A; Sheedy S; Kim B; Suidan R; Sarasohn DM; Nikolovski I; Lakhman Y; McGree ME; Weaver AL; Chi D; Cliby WA
Gynecol Oncol; 2019 Jul; 154(1):72-76. PubMed ID: 31000471
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
[TBL] [Abstract][Full Text] [Related]
12. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
13. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival.
Avesani G; Arshad M; Lu H; Fotopoulou C; Cannone F; Melotti R; Aboagye E; Rockall A
Radiol Med; 2020 Aug; 125(8):770-776. PubMed ID: 32239470
[TBL] [Abstract][Full Text] [Related]
14. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
[TBL] [Abstract][Full Text] [Related]
15. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
16. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.
Chi DS; Eisenhauer EL; Zivanovic O; Sonoda Y; Abu-Rustum NR; Levine DA; Guile MW; Bristow RE; Aghajanian C; Barakat RR
Gynecol Oncol; 2009 Jul; 114(1):26-31. PubMed ID: 19395008
[TBL] [Abstract][Full Text] [Related]
17. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer.
Janco JM; Glaser G; Kim B; McGree ME; Weaver AL; Cliby WA; Dowdy SC; Bakkum-Gamez JN
Gynecol Oncol; 2015 Jul; 138(1):70-7. PubMed ID: 25913130
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS
Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899
[TBL] [Abstract][Full Text] [Related]
19. Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
Muallem MZ; Parashkevova A; Almuheimid J; Richter R; Diab Y; Braicu EI; Sehouli J
Anticancer Res; 2017 Jun; 37(6):3157-3161. PubMed ID: 28551658
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.
Asp M; Malander S; Bengtsson J; Sartor H; Kannisto P
Anticancer Res; 2022 May; 42(5):2541-2551. PubMed ID: 35489749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
